Antihyperglycemic effect of short term resveratrol supplementation in type II diabetes patients
Keywords:Glibenclamide, Metformin, Triglycerides, Resveratrol
To study the effectiveness of resveratrol in decreasing blood glucose in the presence of standard antidiabetic therapy in subjects with type 2 diabetes. There was 1 subject dropout from each group in between the trail. At the end of the trail, there were 20 and 20 subjects in control and intervention group, respectively. There were trends towards a decrease, but no notable changes were noticed in triglycerides, cholesterol, and LDL levels with resveratrol supplementation, while a notable increase in LDL levels was noticed in the control group. Metformin, glibenclamide, and insulin are all known to have favorable or no effect on the lipid profiles therefore, other independent factors may have given to the noticed increase in the control group. Subgroup analyses presented that resveratrol may have an added effect when used in union with glibenclamide and metformin. This is a pilot study which study the antidiabetic effects of resveratrol over the short term, and only one dose of resveratrol was tested. There was no followup to check the metabolic parameters of the patients after the resveratrol wash-out period. The study lacks the enquiring of cellular mechanisms underlying the antidiabetic effects of resveratrol. Lage no.of toxicological screening was not done on subjects to confirm the well being of resveratrol administration, and the safety of administering 1 g dose of resveratrol over the long term has not been established. The present trail bear the strong antidiabetic effect of resveratrol documented in numerous animal studies, as well as the effects evaluated in the human studies. It also bears the case for resveratrol supplementation over a short term. Nevertheless, well-designed clinical trials with resveratrol supplementation in a larger T2DM population and over a longer duration are required to recommend the use of resveratrol independently or as an adjunct in diabetic population.